Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome

作者: Maximilian von Eynatten , Thomas Klein , Michael Mark , Yuliya Sharkovska , Berthold Hocher

DOI:

关键词:

摘要: The present invention relates to methods for treating and/or preventing podocytes related disorders nephrotic syndrome comprising the administration of an effective amount a certain DPP-4 inhibitor, as well use inhibitor metabolic disease in patient with or at risk syndrome.

参考文章(657)
Roberta Baetta, Alberto Corsini, Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. ,vol. 71, pp. 1441- 1467 ,(2011) , 10.2165/11591400-000000000-00000
Yoon-Sik Jun, Ju-Bin Yim, Young Gwan Jo, Ja-Seong Koo, Matrix tablets providing an extended release of metformin ,(2006)
Jerry Meece, When oral agents fail: optimizing insulin therapy in the older adult. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. pp. 11- ,(2009)
Vijay Kumar, Gilbert S. Banker, Maillard Reaction and Drug Stability Maillard reactions in chemistry, food, and health. pp. 20- 27 ,(2005) , 10.1533/9781845698393.1.20
Stephen L. Gwaltney, Jeffrey A. Stafford, Inhibitors of Dipeptidyl Peptidase 4 Annual Reports in Medicinal Chemistry Volume 40. ,vol. 40, pp. 149- 165 ,(2005) , 10.1016/S0065-7743(05)40010-X
Young Sook Rhee, Roger A. Jones, Nitrogen-15-labeled deoxynucleosides. 3. Synthesis of [3-15N]-2'-deoxyadenosine Journal of the American Chemical Society. ,vol. 112, pp. 8174- 8175 ,(1990) , 10.1021/JA00178A056
Baptist Gallwitz, Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. IDrugs : the investigational drugs journal. ,vol. 11, pp. 906- 917 ,(2008)
Joan Goulley, Ulf Dahl, Helena Edlund, Medical use of bmp-2 and/ or bmp-4 ,(2007)